Literature DB >> 24638074

Isolation and quantification of botulinum neurotoxin from complex matrices using the BoTest matrix assays.

F Mark Dunning1, Timothy M Piazza1, Füsûn N Zeytin1, Ward C Tucker2.   

Abstract

Accurate detection and quantification of botulinum neurotoxin (BoNT) in complex matrices is required for pharmaceutical, environmental, and food sample testing. Rapid BoNT testing of foodstuffs is needed during outbreak forensics, patient diagnosis, and food safety testing while accurate potency testing is required for BoNT-based drug product manufacturing and patient safety. The widely used mouse bioassay for BoNT testing is highly sensitive but lacks the precision and throughput needed for rapid and routine BoNT testing. Furthermore, the bioassay's use of animals has resulted in calls by drug product regulatory authorities and animal-rights proponents in the US and abroad to replace the mouse bioassay for BoNT testing. Several in vitro replacement assays have been developed that work well with purified BoNT in simple buffers, but most have not been shown to be applicable to testing in highly complex matrices. Here, a protocol for the detection of BoNT in complex matrices using the BoTest Matrix assays is presented. The assay consists of three parts: The first part involves preparation of the samples for testing, the second part is an immunoprecipitation step using anti-BoNT antibody-coated paramagnetic beads to purify BoNT from the matrix, and the third part quantifies the isolated BoNT's proteolytic activity using a fluorogenic reporter. The protocol is written for high throughput testing in 96-well plates using both liquid and solid matrices and requires about 2 hr of manual preparation with total assay times of 4-26 hr depending on the sample type, toxin load, and desired sensitivity. Data are presented for BoNT/A testing with phosphate-buffered saline, a drug product, culture supernatant, 2% milk, and fresh tomatoes and includes discussion of critical parameters for assay success.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24638074      PMCID: PMC4123472          DOI: 10.3791/51170

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  62 in total

Review 1.  Botulinum neurotoxin: a marvel of protein design.

Authors:  Mauricio Montal
Journal:  Annu Rev Biochem       Date:  2010       Impact factor: 23.643

Review 2.  Botulinum toxin testing in animals: the questions remain unanswered.

Authors:  Michael Balls
Journal:  Altern Lab Anim       Date:  2003-12       Impact factor: 1.303

Review 3.  Applications of Botulinum toxin in urogynaecology.

Authors:  D Sinha; K Karri; A S Arunkalaivanan
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2007-02-02       Impact factor: 2.435

4.  Potency evaluation of a formulated drug product containing 150-kd botulinum neurotoxin type A.

Authors:  Terrence Hunt; Kenneth Clarke
Journal:  Clin Neuropharmacol       Date:  2009 Jan-Feb       Impact factor: 1.592

5.  Quantification of botulinum neurotoxin serotypes A and B from serum using mass spectrometry.

Authors:  Bryan A Parks; Jeffry D Shearer; Jakub Baudys; Suzanne R Kalb; Daniel C Sanford; James L Pirkle; John R Barr
Journal:  Anal Chem       Date:  2011-11-04       Impact factor: 6.986

6.  Identification of the nerve terminal targets of botulinum neurotoxin serotypes A, D, and E.

Authors:  G Schiavo; O Rossetto; S Catsicas; P Polverino de Laureto; B R DasGupta; F Benfenati; C Montecucco
Journal:  J Biol Chem       Date:  1993-11-15       Impact factor: 5.157

Review 7.  Infant botulism.

Authors:  S S Arnon
Journal:  Annu Rev Med       Date:  1980       Impact factor: 13.739

8.  Comparison of fluorigenic peptide substrates PL50, SNAPTide, and BoTest A/E for BoNT/A detection and quantification: exosite binding confers high-assay sensitivity.

Authors:  Tanja Ouimet; Sophie Duquesnoy; Hervé Poras; Marie-Claude Fournié-Zaluski; Bernard P Roques
Journal:  J Biomol Screen       Date:  2013-02-20

9.  Molecular composition and extinction coefficient of native botulinum neurotoxin complex produced by Clostridium botulinum hall A strain.

Authors:  Anne-Marie Bryant; Jenny Davis; Shuowei Cai; Bal Ram Singh
Journal:  Protein J       Date:  2013-02       Impact factor: 2.371

Review 10.  Dose equivalence of two commercial preparations of botulinum neurotoxin type A: time for a reassessment?

Authors:  Kai Wohlfarth; Thomas Sycha; Danièle Ranoux; Hans Naver; David Caird
Journal:  Curr Med Res Opin       Date:  2009-07       Impact factor: 2.580

View more
  1 in total

Review 1.  Alternative Methods for Testing Botulinum Toxin: Current Status and Future Perspectives.

Authors:  Mahesh Raj Nepal; Tae Cheon Jeong
Journal:  Biomol Ther (Seoul)       Date:  2020-07-01       Impact factor: 4.634

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.